BioCentury on BioBusiness,
Emerging Company Profile
Syros mapping, targeting transcriptional regulatory circuits in cancer cells
Related tables, figures and sidebars
Syros: Super maps
Monday, April 15, 2013
Cell identity is specified by complex regulatory networks that
orchestrate cell type-specific gene expression programs. Syros
Pharmaceuticals Inc. is using whole genome methods to define these
networks in cancer cells and to guide the development of small molecules that
selectively inhibit cancer cell growth.
Syros emerged from stealth mode
last week with a $30 million series A round led by Arch Venture Partners and
Flagship Ventures. The announcement coincided with the publication of two papers
in Cell from two of the company's three scientific founders, which
identified a new class of regulatory DNA regions that control genes that
maintain cell identity. In cancer cells, these regions were found upstream of
numerous known oncogenes, including MYC.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]